| Schedule of Investments (unaudited) October 31, 2020 |
iShares® Genomics Immunology and Healthcare ETF (Percentages shown are based on Net Assets) |
|
|
1 |
| Schedule of Investments (unaudited) (continued) October 31, 2020 |
iShares® Genomics Immunology and Healthcare ETF |
Affiliates
Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2020 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
|
|
||||||||||||||||||||||||||||||||||||
| Affiliated Issuer | Value at 07/31/20 |
Purchases at Cost |
Proceeds from Sales |
Net Realized Gain (Loss) |
Change in Unrealized Appreciation (Depreciation) |
Value at 10/31/20 |
Shares Held at 10/31/20 |
Income | Capital Gain from Underlying Funds |
|||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
| BlackRock Cash Funds: Institutional, SL Agency |
$ | 13,668,970 | $ | — | $ | (6,747,165 | )(a) | $ | (3,214 | ) | $ | (153 | ) | $ | 6,918,438 | 6,913,598 | $ | 94,575 | (b) | $ | — | |||||||||||||||
| BlackRock Cash Funds: Treasury, SL Agency |
124,000 | 0 | (a) | — | — | — | 124,000 | 124,000 | 25 | — | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
| $ | (3,214 | ) | $ | (153 | ) | $ | 7,042,438 | $ | 94,600 | $ | — | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
| (a) | Represents net amount purchased (sold). |
| (b) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Fair Value Measurements
Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.
The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of October 31, 2020. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.
|
|
||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
|
|
||||||||||||||||
| Investments |
||||||||||||||||
| Assets |
||||||||||||||||
| Common Stocks |
$ | 158,512,741 | $ | — | $ | — | $ | 158,512,741 | ||||||||
| Money Market Funds |
7,042,438 | — | — | 7,042,438 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| $ | 165,555,179 | $ | — | $ | — | $ | 165,555,179 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Portfolio Abbreviations - Equity | ||
| ADR | American Depositary Receipt | |
| 2 |
|